0.6951

4.86% -0.0355

China Pharma Holdings Inc. (CPHI)

Overview News Price History Discussions Forecast Stock Split

China Pharma Holdings Inc. stock is traded at $0.6951, with a volume of 59,609. It is down -4.86% in the last 24 hours and down -8.50% over the past month. China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.

Previous Close:

$0.7306

Open:

$0.73

24h Volume:

59,609

Relative Volume:

0.22

Market Cap:

$28.17M

Revenue:

$3.99M

Net Income/Loss:

$-3.55M

P/E Ratio:

-1.2618

EPS:

-0.5509

Net Cash Flow:

$94,500

1W Performance:

-11.12%

1M Performance:

-8.50%

6M Performance:

-47.34%

1Y Performance:

-58.62%

1-Day Range:

$0.6951

$0.7656

1-Week Range:

$0.6951

$0.8688

52-Week Range:

$0.3818

$2.0299

China Pharma Holdings Inc. Stock (CPHI) Company Profile

Name

China Pharma Holdings Inc.

Sector

Healthcare (1102)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

86 898 6681 1730

Address

No. 17, Jinpan Road, Second Floor, Haikou

Employee

276

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

CPHI's Discussions on Twitter

Compare CPHI vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPHI China Pharma Holdings Inc.	0.6951	28.17M	3.99M	-3.55M	94,500	-0.5509
TAK Takeda Pharmaceutical Co Adr	15.84	50.05B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	8.95	39.45B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.21	38.67B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.84	32.21B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	544.33	23.11B	3.17B	1.29B	1.01B	27.09

China Pharma Holdings Inc. Stock (CPHI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-10	Initiated	Rodman & Renshaw	Mkt Outperform

China Pharma Holdings Inc. Stock (CPHI) Latest News

Jun 22, 2026

Nuvectis Pharma Expands Pipeline with Exclusive Ex-China Rights to Haisco’s NXP100 and NXP200 Clinical-Stage Candidates - Quiver Quantitative

Jun 22, 2026

Jun 19, 2026

Ascentage Pharma Group International (AAPG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 19, 2026